Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 2/20 | 0.50 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 7/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.43 |
| ▸ | CDC25A | P30304 | 1/20 | 0.42 |
| ▸ | CDC25B | P30305 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL257358 | 0.90 | PDE4D (0.48) | PDE4DPDE4APDE4BPDE4CCDC25A | |
| SCHEMBL10046970 | 0.88 | CDC25A (0.43) | PDE4DPDE4APDE4BPDE4CCDC25A | |
| SCHEMBL257366 | 0.88 | KAT2B (0.53) | KAT2BBAZ2BPDE4DPDE4APDE4B | |
| SCHEMBL15197138 | 0.86 | KAT2B (0.53) | KAT2BBAZ2BPDE4DPDE4APDE4B | |
| SCHEMBL15197137 | 0.80 | KAT2B (0.47) | KAT2BBAZ2BKMT2A | |
| SCHEMBL8890812 | 0.79 | KAT2B (0.71) | KAT2BBAZ2BPDE4DADRB3HSD17B10 | |
| SCHEMBL257355 | 0.77 | PDE5A (0.55) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL15090591 | 0.77 | HSD11B1 (0.47) | KAT2BBAZ2B | |
| SCHEMBL15100752 | 0.77 | HSD11B1 (0.47) | KAT2BBAZ2B | |
| SCHEMBL10046969 | 0.76 | PDE5A (0.44) | KAT2BBAZ2BPDE4DPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895552-B2 | Cyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20130217692-A1 | CYCLIC AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| EP-2612848-A1 | CYCLIC AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012029942-A1 | CYCLIC AMIDE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217692-A1 | CYCLIC AMIDE DERIVATIVE | HDAC10, H1-10, H1-0 | KAT2B 140/4885BAZ2B 1833/4885PDE4D 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.